[
    [
        {
            "time": "2023-02-17",
            "original_text": "珠海明骏及董明珠质押所持99.91%的格力电器股份",
            "features": {
                "keywords": [
                    "珠海明骏",
                    "董明珠",
                    "质押",
                    "格力电器"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "家电"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "珠海明骏及董明珠质押所持99.91%的格力电器股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-02-17",
            "original_text": "天坛生物（600161.SH）：仅为相关血浆疗法提供设备及技术支持，不会对公司主营业务产生影响",
            "features": {
                "keywords": [
                    "天坛生物",
                    "血浆疗法",
                    "设备支持",
                    "技术"
                ],
                "sentiment_score": 0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天坛生物（600161.SH）：仅为相关血浆疗法提供设备及技术支持，不会对公司主营业务产生影响",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-02-17",
            "original_text": "天坛生物：仅为特免血浆疗法提供设备及技术支持",
            "features": {
                "keywords": [
                    "天坛生物",
                    "特免血浆",
                    "设备支持",
                    "技术"
                ],
                "sentiment_score": 0.1,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "天坛生物：仅为特免血浆疗法提供设备及技术支持",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-02-17",
            "original_text": "天坛生物：新冠病毒特免血浆治疗工作由控股股东等开展",
            "features": {
                "keywords": [
                    "天坛生物",
                    "新冠病毒",
                    "特免血浆",
                    "控股股东"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "天坛生物：新冠病毒特免血浆治疗工作由控股股东等开展",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-02-17",
            "original_text": "天坛生物澄清：新型冠状病毒特免血浆疗法属于医疗技术，不属于公司主营业务范畴",
            "features": {
                "keywords": [
                    "天坛生物",
                    "新冠",
                    "特免血浆",
                    "医疗技术",
                    "主营业务"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "天坛生物澄清：新型冠状病毒特免血浆疗法属于医疗技术，不属于公司主营业务范畴",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]